세계 오피오이드 의약품 시장 – 2023-2030

Global Opioids Drug Market - 2023-2030

상품코드PH3002
발행기관DataM Intelligence
발행일2023.06.15
페이지 수195 Pages
포맷PDF + EXCEL
커버리지Global

6,525,00011,775,000

보고서 요약(국문)

시장 개요
전 세계 오피오이드 의약품 시장은 2022년 399억 9,830만 달러에 달했으며, 2030년까지 516억 3,470만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 전 세계 오피오이드 의약품 시장은 예측 기간(2023~2030년) 동안 연평균 3.3%의 성장률을 기록할 것으로 전망됩니다.
오피오이드는 중등도에서 중증의 통증, 특히 수술이나 부상 후 급성 통증, 암 관련 통증, 그리고 말기 질환 환자의 완화 치료 관리에 흔히 처방됩니다. 또한, 오피오이드는 오피오이드 사용 장애가 있는 사람들을 위한 약물 보조 치료(MAT)의 일환으로 사용될 수도 있습니다.
더 나아가, 전 세계 오피오이드 의약품 시장 성장의 주요 동인은 극심한 통증으로 고통받는 환자를 위한 완화 치료의 증가와 오피오이드 남용을 억제하기 위한 남용 방지 제제의 사용 증가입니다. 또한, 수술 후 통증, 암, 섬유근육통, 요통, 관절염과 같은 만성 통증 관련 질환의 발생률 증가도 이러한 질병의 유병률 증가에 기여하고 있습니다.
시장 동향
정신 건강 문제 증가가 오피오이드 시장 성장을 견인할 것으로 예상됩니다.
2022년 유엔 보고서에 따르면 전 세계적으로 약 10억 명이 어떤 형태로든 정신 질환을 앓고 있습니다. 더욱이, 코로나19 팬데믹 첫해에 우울증과 불안 장애와 같은 일반적인 질환 발생률이 25% 이상 증가했습니다.
정신 건강 문제를 동반하는 사람들은 자가 치료의 한 형태로 오피오이드를 찾을 가능성이 더 높습니다. 미국 정신의학협회는 오피오이드가 행복감을 유발하여 부정적인 결과에도 불구하고 지속적인 사용 가능성을 높인다고 밝혔습니다.
오피오이드 남용, 자살률 증가, 정신 건강 문제는 서로 연관되어 있으며, 만성 통증 환자는 정신 건강 문제 발생률이 더 높은 경향이 있습니다. 오피오이드 사용 장애 치료 시 근본적인 정신 건강 문제를 해결하는 것이 매우 중요합니다. 이는 오피오이드를 자가 치료 목적으로 사용하는 것을 방지하고, 물질 사용 장애와 정신 건강 문제 모두에 적절한 치료를 제공하기 위함입니다.
오피오이드 약물의 위험과 부작용은 세계 오피오이드 약물 시장의 성장을 저해하고 있습니다.
오피오이드 약물은 여러 가지 위험과 잠재적인 부작용을 수반합니다. 장기간 사용 시 신체적 의존성과 중독으로 이어질 수 있으며, 이는 금단 증상과 갈망을 유발합니다. 또한 오피오이드는 호흡계를 억제하여 고용량 투여 시 또는 다른 호흡 억제제와 병용 시 호흡 곤란이나 호흡 정지를 초래할 수 있습니다.
예를 들어, 모르핀은 천연 오피오이드이며 가장 오래된 진통제 중 하나입니다. 병원에서 심한 통증 완화를 위해 자주 사용됩니다. 모르핀을 장기간 사용하면 의존성과 중독으로 이어질 수 있습니다. 따라서 이러한 요인들로 인해 시장은 예측 기간 동안 성장이 저해될 것으로 예상됩니다.

COVID-19 영향 분석
COVID-19 팬데믹은 오피오이드 약물의 사용 및 공급에 상당한 영향을 미쳤습니다. 팬데믹은 전 세계 의료 시스템을 마비시켜 약물 남용 치료 및 지원을 포함한 필수 서비스 접근성을 저해했습니다. 많은 중독 치료 센터와 클리닉은 대면 방문을 제한하거나 일시적으로 문을 닫아야 했고, 이로 인해 오피오이드 중독으로 어려움을 겪는 사람들에게 필수적인 자원에 대한 접근성이 감소했습니다.
팬데믹은 전례 없는 수준의 스트레스, 불안, 사회적 고립을 초래했습니다. 이러한 요인들은 기존의 약물 사용 장애를 악화시키고 오피오이드 남용의 시작이나 심화에 기여할 수 있습니다. 경제적 어려움, 실직, 슬픔, 제한된 사회적 지원 네트워크는 모두 약물 사용 증가와 오피오이드 중독에 대한 취약성을 야기할 수 있습니다.
팬데믹에 대응하여 의료 서비스 제공자들은 원격 진료 및 처방 서비스를 제공하기 위해 원격 의료를 점점 더 많이 활용했습니다. 원격 의료는 의료 서비스 접근성을 유지하는 데 도움이 되었지만, 오피오이드 약물의 적절한 사용을 모니터링하고 규제하는 데에는 어려움도 제기했습니다. 일부 사례에서는 적절한 평가, 후속 조치 또는 감독 없이 원격 처방이 증가했을 수 있으며, 이는 부적절하거나 과도한 오피오이드 처방으로 이어질 가능성이 있습니다.
러시아-우크라이나 분쟁 분석
우크라이나와 러시아 간의 분쟁은 세계 오피오이드 시장에 직접적인 영향을 미치지 않았습니다. 그러나 오피오이드를 포함한 불법 마약 거래는 특정 지역의 분쟁 및 불안정을 포함한 다양한 지정학적 요인의 영향을 받을 수 있다는 점에 유의해야 합니다.
일반적으로 마약 생산 또는 밀매 활동이 활발한 지역의 분쟁과 혼란은 마약 공급의 가용성과 경로에 영향을 미칠 수 있습니다. 분쟁은 마약 밀매 경로의 변화나 불법 약물의 생산 및 유통 방식의 변화로 이어질 수 있습니다. 이러한 변화는 오피오이드의 가용성과 가격을 포함하여 세계 마약 시장에 파급 효과를 미칠 수 있습니다.
세분화 분석
세계 오피오이드 시장은 제품, 용도, 유통 채널 및 지역별로 세분화됩니다.

통증 관리 부문은 예측 기간 동안 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
통증 관리 부문은 오피오이드 약물 시장의 약 37.8%를 차지하며 가장 높은 시장 점유율을 보였습니다. 오피오이드 약물은 특히 급성 및 중증 통증 관리에 여러 가지 이점을 제공합니다. 이 약물들은 뇌와 척수의 오피오이드 수용체에 결합하여 통증 신호 전달을 감소시키고 진통 효과를 나타냅니다. 따라서 수술 후, 외상성 손상 또는 임종 치료 중 통증 관리에 유용합니다.
다양한 제형으로 제공되어 투여량 및 투여 방식에 유연성을 제공합니다. 속효성 제제, 서방형 제제, 경피 패치, 경구 용액 및 주사제 제형이 있습니다. 이러한 다양성을 통해 의료진은 개별 환자의 요구에 맞춰 치료를 조정하고 통증 관리를 최적화할 수 있습니다.
예를 들어, 모르핀과 펜타닐은 작용 발현이 빠릅니다. 이러한 신속한 통증 완화는 수술이나 심각한 부상과 같이 즉각적인 통증 조절이 필요한 급성 상황에서 매우 중요할 수 있습니다. 또한, 오피오이드는 지속적인 통증 관리에도 불구하고 갑자기 발생하는 극심한 통증인 돌발성 통증을 효과적으로 관리할 수 있습니다. 속효성 모르핀이나 옥시코돈과 같은 속효성 오피오이드는 이러한 돌발성 통증 발생 시 신속한 통증 완화를 제공하는 응급 약물로 사용될 수 있습니다. 따라서 위와 같은 요인으로 인해 해당 시장 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
지역 분석
정형외과 질환 발생률 증가, 만성 질환 유병률 증가, 주요 시장 참여 기업의 존재로 북미 지역이 시장을 주도하고 있습니다.
북미는 예측 기간 동안 전체 시장 점유율의 약 42.4%를 차지할 것으로 추정됩니다. 예를 들어, 미국 통증 재단(U.S. Pain Foundation)의 2022년 보고서에 따르면, 약 5천만 명의 미국인이 대부분의 날에 3개월 이상 지속되는 만성 통증을 경험하고 있습니다. 이 중 2천만 명은 일상생활, 특히 개인위생 및 가사 활동에 지장을 주는 심각한 만성 통증을 겪고 있습니다.

통증으로 인한 재정적 손실은 상당하며, 직접적인 의료비와 생산성 손실을 포함하여 국가적으로 연간 최소 5,600억~6,350억 달러의 비용이 발생하는 것으로 추산됩니다. 따라서 이러한 요인들을 고려할 때, 북미 지역이 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., West-Ward Pharmaceuticals Corporation, Pfizer Inc., Cipher Pharmaceuticals Inc., Lupin Ltd., Allergan PLC, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited, Grunenthal GmbH, China Aoxing Pharmaceutical Company, Inc. 등이 있습니다.
보고서 ​​구매 이유

• 제품, 적용 분야, 유통 채널 및 지역별 글로벌 오피오이드 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해 • 모든 세그먼트를 포함한 오피오이드 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품들을 정리한 제품 맵핑 엑셀 파일 제공.

글로벌 오피오이드 시장 보고서는 약 61개의 표, 62개의 그림, 195페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global opioids drug market reached US$ 39,998.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 51,634.7 million by 2030. The global opioids drug market is expected to exhibit a CAGR of 3.3% during the forecast period (2023-2030).
Opioid drugs are commonly prescribed for the management of moderate to severe pain, particularly acute pain following surgeries or injuries, cancer-related pain, and palliative care for patients with advanced illnesses. Opioids may also be used as part of medication-assisted treatment (MAT) for individuals with opioid use disorders.
Furthermore, the key drivers contributing to the global opioid drug market's growth are escalating palliative care for patients suffering intensely and using abuse-deterrent preparations to restrict opioid abuse. Also, the growing occurrence of chronic pain-related conditions like post-surgical pain, cancer, fibromyalgia, lower back pain, and arthritis is contributing to the increasing prevalence of these diseases.
Market Dynamics
Increasing Mental Health Conditions are Expected to Drive Opioid Drugs Market Growth.
According to United Nations Report 2022, Nearly one billion people worldwide suffer from some form of mental disorder. Moreover, in the first year of the COVID-19 pandemic, rates of common conditions such as depression and anxiety went up by more than 25 percent.
Individuals who have co-occurring mental health disorders are more susceptible to seeking opioids as a form of self-medication. The American Psychiatric Association states that opioids can induce feelings of euphoria, increasing the likelihood of continued use despite negative consequences.
The opioid epidemic, rising suicide rates, and mental health issues are interconnected, and individuals with chronic pain often experience higher rates of mental health disorders. It is crucial to address underlying mental health conditions when treating opioid use disorder to prevent the use of opioids for self-medication and provide appropriate treatment for both the substance use disorder and the mental health condition.
The Risks and Side Effects of Opioid Drugs are Hampering the Growth of the Global Opioid Drugs Market.
Opioid drugs carry several risks and potential side effects, including prolonged use of opioids can lead to physical dependence and addiction, characterized by cravings and withdrawal symptoms upon discontinuation and opioids can depress the respiratory system, potentially causing slowed breathing or even respiratory arrest in high doses or when combined with other respiratory depressants.
For instance, morphine is a natural opioid and one of the oldest known pain medications. It is frequently used in hospital settings for severe pain relief. Prolonged use of morphine can lead to dependence and addiction. Thus, owing to the above factors, the market is expected to hamper over the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the use and availability of opioid drugs. The pandemic has disrupted healthcare systems worldwide, affecting access to essential services, including substance abuse treatment and support. Many addiction treatment centers and clinics had to limit in-person visits or temporarily close, reducing access to vital resources for individuals struggling with opioid addiction.
The pandemic has brought about unprecedented levels of stress, anxiety, and social isolation. These factors can exacerbate existing substance use disorders and contribute to the initiation or escalation of opioid misuse. Financial hardships, loss of employment, grief, and limited social support networks can all contribute to increased substance use and vulnerability to opioid addiction.
In response to the pandemic, healthcare providers increasingly turned to telemedicine to provide remote consultations and prescription services. While telemedicine helped maintain access to healthcare, it also presented challenges in monitoring and regulating the appropriate use of opioid medications. In some cases, there may have been an increase in remote prescribing without adequate assessments, follow-up, or oversight, potentially leading to inappropriate or excessive opioid prescriptions.
Russia-Ukraine Conflict Analysis
The Ukraine and Russia conflict has not had a direct impact on the global opioid drug market. However, it is important to note that the illicit drug trade, including opioids, can be influenced by various geopolitical factors, including conflicts and instability in certain regions.
In general, conflicts and disruptions in regions with drug production or trafficking activities can affect the availability and routes of drug supply. It is possible that conflicts can lead to shifts in drug trafficking routes or changes in the production and distribution of illicit substances. These changes can have ripple effects on the global drug market, including the availability and pricing of opioids.
Segment Analysis
The global opioid drugs market is segmented based on product, application, distribution channel, and region.
The Pain Management Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period.
The pain management segment accounted for the highest market stake accounting for approximately 37.8% of the opioid drugs market. Opioid drugs offer several advantages in pain management, particularly for acute and severe pain. They work by binding to opioid receptors in the brain and spinal cord, reducing the transmission of pain signals and producing analgesic effects. This makes them valuable for managing pain after surgery, traumatic injuries, or during end-of-life care.
They are available in various formulations, allowing for flexibility in dosing and administration. They come in immediate-release forms, extended-release formulations, transdermal patches, oral solutions, and injectable formulations. This versatility allows healthcare providers to tailor the treatment to individual patient needs and optimize pain management.
For instance, morphine and fentanyl, have a rapid onset of action. This quick pain relief can be crucial in acute situations where immediate pain control is required, such as during surgical procedures or severe injuries.
Furthermore, opioids can effectively manage breakthrough pain, which refers to sudden and intense episodes of pain that occur despite ongoing pain management. Quick-acting opioids, such as immediate-release morphine or oxycodone, can be used as rescue medications to provide rapid relief during these episodes. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.
Geographical Analysis
The Rising Incidence of Orthopedic Diseases, the Increasing Prevalence of Chronic Diseases, and the Presence of Key Market Players Dominate the North American Region
North America is estimated to hold around 42.4% of the total market share throughout the forecast period. For instance, according to U.S. Pain Foundation Report 2022, approximately 50 million Americans experience chronic pain, lasting for three months or more on most days. Among them, 20 million individuals have high-impact chronic pain, which hinders their ability to perform basic daily activities, including personal hygiene and household chores.
The financial implications of pain are substantial, with estimates suggesting that it costs the nation a minimum of $560-635 billion annually in terms of direct medical expenses and productivity losses. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.
Competitive Landscape
The major global players in the market include Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., West-Ward Pharmaceuticals Corporation, Pfizer Inc., Cipher Pharmaceuticals Inc., Lupin Ltd., Allergan PLC, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited, Grunenthal GmbH, and China Aoxing Pharmaceutical Company, Inc. among others.
Why Purchase the Report?
• To visualize the global opioids drug market segmentation based on the product, application, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of opioids drug market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global opioids drug market report would provide approximately 61 tables, 62 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product
3.2. Snippet by Application
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing mental health conditions
4.1.2. Restraints
4.1.2.1. The risks and side effects of opioid drugs
4.1.3. Opportunity
4.1.3.1. Ongoing research in the field of opioids
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. By Product
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
8.1.2. Market Attractiveness Index, By Product
8.2. Buprenorphine*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Fentanyl
8.4. Hydrocodone
8.5. Morphine
8.6. Oxycodone
8.7. Others
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Pain management*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Anesthesia
9.4. Cough suppression
9.5. Diarrhea treatment
9.6. Opioid addiction treatment
9.7. Others
10. By Distribution Channel
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. U.K.
11.3.6.3. France
11.3.6.4. Italy
11.3.6.5. Spain
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. Australia
11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies
13. Company Profiles
13.1. Purdue Pharma L.P.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Janssen Pharmaceuticals, Inc.
13.3. West-Ward Pharmaceuticals Corporation
13.4. Pfizer Inc.
13.5. Cipher Pharmaceuticals Inc.
13.6. Lupin Ltd.
13.7. Allergan PLC
13.8. Sanofi-Aventis S.A.
13.9. Sun Pharmaceutical Industries Limited
13.10. Grunenthal GmbH
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Purdue Pharma L.P., 4. Key Developments, Janssen Pharmaceuticals, Inc., West-Ward Pharmaceuticals Corporation, Pfizer Inc., Cipher Pharmaceuticals Inc., Lupin Ltd., Allergan PLC, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited, Grunenthal GmbH

표 목록 (Tables)

List of Tables

Table 1 Global Opioids Drug Market Value, By Product, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Opioids Drug Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Opioids Drug Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Opioids Drug Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Opioids Drug Market Value, By Product, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Opioids Drug Market Value, By Product, 2022-2031 (US$ Million)

Table 7 Global Opioids Drug Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Opioids Drug Market Value, By Application, 2022-2031 (US$ Million)

Table 9 Global Opioids Drug Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Opioids Drug Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Opioids Drug Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Opioids Drug Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Opioids Drug Market Value, By Product, 2022-2031 (US$ Million)

Table 14 North America Opioids Drug Market Value, By Application, 2022-2031 (US$ Million)

Table 15 North America Opioids Drug Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Opioids Drug Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Opioids Drug Market Value, By Product, 2022-2031 (US$ Million)

Table 18 South America Opioids Drug Market Value, By Application, 2022-2031 (US$ Million)

Table 19 South America Opioids Drug Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Opioids Drug Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Opioids Drug Market Value, By Product, 2022-2031 (US$ Million)

Table 22 Europe Opioids Drug Market Value, By Application, 2022-2031 (US$ Million)

Table 23 Europe Opioids Drug Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Opioids Drug Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Opioids Drug Market Value, By Product, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Opioids Drug Market Value, By Application, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Opioids Drug Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Opioids Drug Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Opioids Drug Market Value, By Product, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Opioids Drug Market Value, By Application, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Opioids Drug Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Purdue Pharma L.P.: Overview

Table 33 Purdue Pharma L.P.: Product Portfolio

Table 34 Purdue Pharma L.P.: Key Developments

Table 35 Janssen Pharmaceuticals, Inc.: Overview

Table 36 Janssen Pharmaceuticals, Inc.: Product Portfolio

Table 37 Janssen Pharmaceuticals, Inc.: Key Developments

Table 38 West-Ward Pharmaceuticals Corporation: Overview

Table 39 West-Ward Pharmaceuticals Corporation: Product Portfolio

Table 40 West-Ward Pharmaceuticals Corporation: Key Developments

Table 41 Pfizer Inc.: Overview

Table 42 Pfizer Inc.: Product Portfolio

Table 43 Pfizer Inc.: Key Developments

Table 44 Cipher Pharmaceuticals Inc.: Overview

Table 45 Cipher Pharmaceuticals Inc.: Product Portfolio

Table 46 Cipher Pharmaceuticals Inc.: Key Developments

Table 47 Lupin Ltd.: Overview

Table 48 Lupin Ltd.: Product Portfolio

Table 49 Lupin Ltd.: Key Developments

Table 50 Allergan PLC: Overview

Table 51 Allergan PLC: Product Portfolio

Table 52 Allergan PLC: Key Developments

Table 53 Sanofi-Aventis S.A.: Overview

Table 54 Sanofi-Aventis S.A.: Product Portfolio

Table 55 Sanofi-Aventis S.A.: Key Developments

Table 56 Sun Pharmaceutical Industries Limited: Overview

Table 57 Sun Pharmaceutical Industries Limited: Product Portfolio

Table 58 Sun Pharmaceutical Industries Limited: Key Developments

Table 59 Grunenthal GmbH: Overview

Table 60 Grunenthal GmbH: Product Portfolio

Table 61 Grunenthal GmbH: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 2 Global Opioids Drug Market Share, By Product, 2022 & 2031 (%)

Figure 3 Global Opioids Drug Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global Opioids Drug Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Opioids Drug Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Opioids Drug Market Y-o-Y Growth, By Product, 2022-2030 (%)

Figure 7 Buprenorphine Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 8 Fentanyl Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 9 Hydrocodone Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 10 Morphine Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 11 Oxycodone Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 12 Others Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 13 Global Opioids Drug Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 14 Pain Management Application in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 15 Anesthesia Application in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 16 Cough Suppression Application in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 17 Diarrhea Treatment Application in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 18 Opioid addiction treatment Application in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 19 Global Opioids Drug Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 20 Hospital Pharmacies Distribution Channel in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 21 Retail Pharmacies Distribution Channel in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 22 Online Pharmacies Distribution Channel in Global Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 23 Global Opioids Drug Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 25 Asia-Pacific Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 26 Europe Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 27 South America Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 28 Middle East and Africa Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 29 North America Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 30 North America Opioids Drug Market Share, By Product, 2022 & 2031 (%)

Figure 31 North America Opioids Drug Market Share, By Application, 2022 & 2031 (%)

Figure 32 North America Opioids Drug Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 33 North America Opioids Drug Market Share, By Country, 2022 & 2031 (%)

Figure 34 South America Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 35 South America Opioids Drug Market Share, By Product, 2022 & 2031 (%)

Figure 36 South America Opioids Drug Market Share, By Application, 2022 & 2031 (%)

Figure 37 South America Opioids Drug Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 38 South America Opioids Drug Market Share, By Country, 2022 & 2031 (%)

Figure 39 Europe Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 40 Europe Opioids Drug Market Share, By Product, 2022 & 2031 (%)

Figure 41 Europe Opioids Drug Market Share, By Application, 2022 & 2031 (%)

Figure 42 Europe Opioids Drug Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 43 Europe Opioids Drug Market Share, By Country, 2022 & 2031 (%)

Figure 44 Asia-Pacific Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 45 Asia-Pacific Opioids Drug Market Share, By Product, 2022 & 2031 (%)

Figure 46 Asia-Pacific Opioids Drug Market Share, By Application, 2022 & 2031 (%)

Figure 47 Asia-Pacific Opioids Drug Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 48 Asia-Pacific Opioids Drug Market Share, By Country, 2022 & 2031 (%)

Figure 49 Middle East & Africa Opioids Drug Market Value, 2022-2031 (US$ Million)

Figure 50 Middle East & Africa Opioids Drug Market Share, By Product, 2022 & 2031 (%)

Figure 51 Middle East & Africa Opioids Drug Market Share, By Application, 2022 & 2031 (%)

Figure 52 Middle East & Africa Opioids Drug Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 53 Purdue Pharma L.P.: Financials

Figure 54 Janssen Pharmaceuticals, Inc.: Financials

Figure 55 West-Ward Pharmaceuticals Corporation: Financials

Figure 56 Pfizer Inc.: Financials

Figure 57 Cipher Pharmaceuticals Inc.: Financials

Figure 58 Lupin Ltd.: Financials

Figure 59 Allergan PLC: Financials

Figure 60 Sanofi-Aventis S.A.: Financials

Figure 61 Sun Pharmaceutical Industries Limited: Financials

Figure 62 Grunenthal GmbH: Financials